Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eighteen ratings firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $30.18.

NRIX has been the topic of several research reports. Stifel Nicolaus lowered their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Wells Fargo & Company lowered their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, April 9th. Wall Street Zen downgraded Nurix Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Leerink Partnrs upgraded Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 29th.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,438 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $28,037.00. Following the completion of the transaction, the chief financial officer now owns 39,922 shares of the company's stock, valued at $459,103. The trade was a 5.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now directly owns 61,516 shares in the company, valued at $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,013 shares of company stock valued at $137,096. Insiders own 7.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE boosted its holdings in shares of Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after acquiring an additional 842 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Nurix Therapeutics in the 4th quarter worth about $28,000. Aquatic Capital Management LLC bought a new stake in Nurix Therapeutics in the 4th quarter valued at about $87,000. Exchange Traded Concepts LLC boosted its stake in Nurix Therapeutics by 38.9% during the 1st quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock valued at $109,000 after purchasing an additional 2,562 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new position in Nurix Therapeutics during the 1st quarter valued at about $122,000.

Nurix Therapeutics Trading Up 2.0%

Shares of NASDAQ:NRIX traded up $0.25 during trading on Tuesday, hitting $12.79. 613,957 shares of the stock were exchanged, compared to its average volume of 885,641. The company has a market cap of $975.06 million, a PE ratio of -4.43 and a beta of 2.15. Nurix Therapeutics has a 12-month low of $8.18 and a 12-month high of $29.56. The company has a fifty day moving average price of $10.42 and a two-hundred day moving average price of $15.22.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the prior year, the company earned ($0.76) EPS. Equities research analysts anticipate that Nurix Therapeutics will post -2.99 earnings per share for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.